Clinical Data, Inc. To Present At The Toxicogenomics And Personalized Medicine Symposium At The New York Academy Of Sciences
Dr. Reed's presentation, "Pharmacogenetic Tests for Rare SAEs", which starts at 1:50 pm, will focus on the value of individualizing treatment based on a patient's genetics. Numerous examples now show that pharmacogenetic tests can be developed for the prediction of rare but serious adverse events associated with specific therapeutic agents. It is estimated that such serious drug reactions account for 5 to 7 percent of hospital admission in the U.S. and Europe and cost the U.S. society up to 4 billion dollars per year. In response to the growing awareness of the implications of serious adverse drug events and their possible avoidance, the FDA has recently added information about genetic predictors of these events to drug labeling. Dr. Reed's lecture will review the status of pharmacogenetic tests to predict serious adverse drug events and provide examples of currently available tests aimed at bringing personalized medicine to the forefront of patient care. The conference is open to the public. For more information, please visit, http://www.nyas.org/toxicology.
Date: Monday, February 4, 2008
Time: 1:00 pm -5:30 pm EDT
Place: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St. at Barclay St., 40th fl
About The New York Academy of Sciences
Founded in 1817, the New York Academy of Sciences is an independent, nonprofit organization with 26,000 members in 140 countries. The Society's mission is to advance scientific knowledge, positively impact the major global challenges of society with solutions that are science-based, and increase the number of scientifically informed individuals in society at large.
About Clinical Data, Inc.
Clinical Data, Inc. is a global biotechnology company unlocking the potential of molecular discovery, From Targeted Science to Better Healthcare™. Its PGxHealth™ division focuses on proprietary biomarker and pharmacogenetic test development as well as targeted therapeutics to help predict drug safety and efficacy, thereby reducing health care costs and improving clinical outcomes. Its Cogenics™ division provides genomics services to both research and regulated environments. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists and health plans worldwide. Visit the company's website at http://www.clda.com for more information.
Clinical Data, Inc.
Date clinice, Inc sã prezinte, la Toxicogenomics ºi personalizate medicament simpozion la New York, Academia de ªtiinþe - Clinical Data, Inc. To Present At The Toxicogenomics And Personalized Medicine Symposium At The New York Academy Of Sciences - articole medicale engleza - startsanatate